Search
Advanced search

Company search

Company/VAT no/Free text Country/City/Municipality

TURNOVER (x1000 SEK)

NET PROFIT (x1000 SEK)

EMPLOYEES

Octapharma Nordic AB

Closing information (x1000 SEK)

Closing information 2024/12 (consolidated) 2023/12 (consolidated) 2022/12 (consolidated)
Turnover 39,712,986 Less Arrow 36,237,639 Less Arrow 31,741,662
Financial expenses 100,702 Less Arrow 20,239 More Arrow 37,403
Earnings before taxes 6,192,719 Less Arrow 4,884,881 More Arrow 5,693,016
EBITDA 7,857,195 Less Arrow 6,446,532 More Arrow 7,246,421
Total assets 56,707,955 Less Arrow 49,185,949 Less Arrow 47,108,542
Current assets 43,116,012 Less Arrow 36,376,949 Less Arrow 33,692,804
Current liabilities 5,473,082 Less Arrow 4,611,853 Less Arrow 4,440,123
Equity capital 48,769,676 Less Arrow 42,505,059 Less Arrow 40,274,418
- share capital 1,375 Less Arrow 1,332 More Arrow 1,335
Employees (average) 10,501 More Arrow 10,587 Less Arrow 9,734

Financial ratios

Fiscal year 2024/12 (consolidated) 2023/12 (consolidated) 2022/12 (consolidated)
Solvency 86.0% More Arrow 86.4% Less Arrow 85.5%
Turnover per employee 3,782 Less Arrow 3,423 Less Arrow 3,261
Profit as a percentage of turnover 15.6% Less Arrow 13.5% More Arrow 17.9%
Return on assets (ROA) 11.1% Less Arrow 10.0% More Arrow 12.2%
Current ratio 787.8% More Arrow 788.8% Less Arrow 758.8%
Return on equity (ROE) 12.7% Less Arrow 11.5% More Arrow 14.1%
Change turnover 3,475,347 More Arrow 4,495,977 More Arrow 6,013,501
Change turnover % 10% More Arrow 14% More Arrow 23%
Chg. No. of employees -86 More Arrow 853 More Arrow 1,398
Chg. No. of employees % -1% More Arrow 9% More Arrow 17%

Total value of public sale

Fiscal year 2024/12 (consolidated) 2023/12 (consolidated) 2022/12 (consolidated)
Total value of public sale 0 Equal arrow 0 Equal arrow 0

Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank

The closing information is gathered directly from the companies or from Creditsafe.